Merck Group, Switzerland

Previous Program Leader Biosimilars Partnership, Global Strategic Excellence – Business Operations & Strategy

Marina has been working in the pharmaceutical industry for almost two decades. She has worked with MSD, Sandoz, Novartis, GSK and Merck covering Pharma, Generics, OTC and Biosimilars. At the very beginning of her career, Marina has been part of the extended team at Sandoz developing the first biosimilars in the market (Somatropin approved in the EU in 2006). In her latest role at Merck she has contributed to the development of the first tocilizumab biosimilar, which has received a positive CHMP* opinion in July 2023. *Committee for Medicinal Products for Human Use


Register for the Biosimilars LatAm – Europe 2023